ClinicalTrials.gg
Not yet recruitingNCT07939594Updated Nov 16, 2026

An Evaluation of the Potential for VH4011499 Drug-drug-interactions

A Phase 1 interventional study of VH4011499 and Ritonavir in HIV Infections, sponsored by ViiV Healthcare. Not yet recruiting. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Basic science

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
75
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 266 studies in HIV Infections by GlaxoSmithKline — 15 open to participants now, 27 under way, 8 of them phase 3. HIV Infections · GlaxoSmithKline.

Planned enrollment
109th of 210
75 · median 82
Started
2026
with 9 others
Phase 1
83 of 266
9 open now
Primary completion
2027-03
later than 14 of 26 live
Registered
266th of 266
by date

Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 109th largest by planned enrollment of the 210 interventional ones that give a count, is one of 10 that started in 2026, is one of 83 in phase 1, reaches primary completion later than 14 of the 26 other live ones, and was the 266th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

Browse HIV Infections studies →

Open to participants now

15 of the 266 studies in HIV Infections by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in HIV Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the pharmacokinetic (PK) interactions between VH4011499 and representative drugs containing inhibitors and inducers, selected transporters, and statins, in HIV negative adults. The study will also assess to assess safety and tolerability during co-administration of VH4011499 with the selected drugs.

03

Conditions studied

  • HIV Infections

Keywords

  • VH4011499
  • Human immunodeficiency virus (HIV)
  • Pharmacokinetic interactions
  • Drug-Drug Interaction (DDI)Ritonavir
  • Efavirenz
  • Carbamazepine
  • Metformin
  • Digoxin
  • Rosuvastatin
  • Pitavastatin
  • Safety
  • Adverse events
  • Tolerability
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be 18 to 60 years of age inclusive at the time of signing the form (ICF).
  • Male or female:

    1. Male Participants:

      No restrictions for male participants.

    2. A female participant (female sex assigned at birth) is eligible to participate if:

They are a woman of non-child bearing potential (WONCBP). There is no requirement for female study participants to use a highly effective method of since, to be eligible, they must be of nonchildbearing potential.

  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, vital signs, cardiac monitoring, and clinical laboratory evaluations at Screening.
  • Body weight ≥50.0 kg (110 lbs) for men and ≥45.0 kg (99 lbs) for women and within the range 18.5 to 32.0 kg/m\^2 (inclusive).
  • Capable of giving signed informed consent.

Exclusion criteria

Exclusion Criteria:

  • History or presence of clinical condition or disorder that could be capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study drugs, interfering with the interpretation of data or would make the participant unsuitable for the study; unable to comply with dosing requirements; or unable to comply with study visits.
  • Pre-existing , gastro-intestinal pathology or diagnosis.
  • A history, or current abnormality in glucose metabolism requiring concomitant use of insulin or other medications for glucose control.
  • Clinically significant abnormal blood pressure at Screening.
  • Lymphoma, leukemia, or any within the past 5 years (with specified exceptions) or breast cancer within the past 10 years.
  • Breast cancer within the past 10 years.
  • Current or chronic history of liver disease or known hepatic or biliary abnormalities, or history of hepatic porphyria.
  • History of syncope, clinically significant palpitations, cardiac arrhythmias or other cardiac diseases or a family and personal history of long syndrome.
  • History of seizure(s) and / or other clinically significant neurological conditions.
  • Pre-existing psychiatric condition, that would pose a safety risk to the participant or interfere with participation in the study.
  • Participants with any history of any drug , delayed-type hypersensitivity, or severe hypersensitivity reactions, as well as history of sensitivity to the study interventions.
  • Participant is mentally or legally incapacitated.
  • Cohort 3: VH4011499 + Carbamazepine ONLY: Participants who are carriers of the HLA-B*15:02 and/or HLA-A*31:01 gene.
  • Cohort 3: VH4011499 + Carbamazepine ONLY: History of bone marrow depression, aplastic anemia, agranulocytosis, or other clinically significant hematologic or bone marrow disorder.
  • Unable to refrain from the use of prescription or non-prescription medications.
  • Use of monoamine oxidase inhibitors (MAOIs) within 14 days prior to Day -1.
  • Cohort 3:VH4011499 + Carbamazepine ONLY: Known hypersensitivity to carbamazepine, oxcarbazepine, or tricyclic compounds.
  • Exposure to more than 4 new products within 12 months prior to the first dosing day.
  • Current enrollment or past participation in another investigational study in which an investigational intervention, within the protocol-defined exclusion period.
  • Participant has donated or lost blood, or has donated plasma within 30 days prior to first administration.
  • Current enrollment or past participation in this clinical study.
  • Unwillingness or inability to follow the procedures outlined in the protocol.
  • \<90 mL/min or serum creatinine >1.1× (ULN) .
  • \<12.5 g/dL for men and \<11 g/dL for women.
  • Participants with active virus (HBV) based on any of the following are excluded: 1) Positive hepatitis B surface antigen (HBsAg), 2) Positive hepatitis B surface antibody (HBcAb) except HBV DNA is negative.
  • Positive antibody test result at Screening.
  • Positive pre-study drug/alcohol screen.
  • Positive -1 antibody / antigen fourth generation test (point of care test or laboratory immunoassay) and / or acute viral symptoms with no alternative etiology within 3 weeks prior to Screening.
  • Cohort 3: VH4011499 + Carbamazepine ONLY: Clinically significant hematologic abnormalities at Screening.
  • Cohort 3: VH4011499 + Carbamazepine ONLY: Serum sodium \<135 millimole/L.
  • Regular alcohol consumption within 6 months prior to Screening.
  • Regular use of known drugs of abuse.
  • Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to Screening and at admission.
  • Sensitivity to the study drugs, or components thereof, or other drug or other allergy that, contraindicates participation in the study.
  • Prior exposure to VH4011499 or Lenacapavir in any formulation..
  • Study participants with >1.0x ULN or total >1.5x ULN are excluded at Screening.
  • Any significant arrhythmia or findings meeting protocol-defined exclusion criteria.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Cohort 1: VH4011499 + Ritonavir

    Participants receive a single dose of VH4011499 at Day 1, followed by a 21-day washout period. On days 23-54, participants receive Ritonavir twice daily. On Day 26, participants receive another single dose of VH4011499, along with Ritonavir.

    Drug: VH4011499 · Drug: Ritonavir

  • Experimental
    Cohort 2: VH4011499 + Efavirenz

    Participants receive a single dose of VH4011499 at Day 1, followed by a 21-day washout period. On days 23-58, participants receive Efavirenz once daily. On Day 37, participants receive another single dose of VH4011499, along with Efavirenz.

    Drug: VH4011499 · Drug: Efavirenz

  • Experimental
    Cohort 3: VH4011499 + Carbamazepine

    Participants receive a single dose of VH4011499 at Day 1, followed by a 21-day washout period. On days 23-25, participants receive Carbamazepine low dose; on days 26-28, they receive Carbamazepine medium dose; and on days 29-62, they receive Carbamazepine high dose. On Day 41, the participants receive another single dose of VH4011499, along with Carbamazepine high dose.

    Drug: VH4011499 · Drug: Carbamazepine

  • Experimental
    Cohort 4: VH4011499 + Metformin + Digoxin

    Participants receive a dose of Metformin and Digoxin on Day 1, followed by a 14-day washout period. On days 10-24, participants receive VH4011499 once daily (a higher dose on Day 10, followed by a lower dose on days 11-24). On Day 16, participants receive another dose of Metformin and Digoxin, along with VH4011499.

    Drug: VH4011499 · Drug: Metformin · Drug: Digoxin

  • Experimental
    Cohort 5: VH4011499 + Rosuvastatin + Pitavastatin

    Participants receive a dose of Rosuvastatin on Day 1, and a dose of Pitavastatin on Day 5, followed by a 10-day washout period. On days 11-26, participants receive VH4011499 once daily (a higher dose on Day 11, followed by a lower dose on days 12-26). On Day 17, participants receive another dose of Pitavastatin, and on Day 22 they receive another dose of Rosuvastatin, along with VH4011499.

    Drug: VH4011499 · Drug: Rosuvastatin · Drug: Pitavastatin

Interventions

  • VH4011499 is administered to the participants based on the protocol schedule.

  • Ritonavir is administered to the participants based on the protocol schedule.

  • DrugEfavirenz

    Efavirenz is administered to the participants based on the protocol schedule.

  • DrugCarbamazepine

    Carbamazepine is administered to the participants based on the protocol schedule.

  • DrugMetformin

    Metformin is administered to the participants based on the protocol schedule.

  • DrugDigoxin

    Digoxin is administered to the participants based on the protocol schedule.

  • DrugRosuvastatin

    Rosuvastatin is administered to the participants based on the protocol schedule.

  • Pitavastatin is administered to the participants based on the protocol schedule.

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration (Cmax) of VH4011499 when administered alone

    Time frame: Day 1 for Cohorts 1, 2 and 3

  2. Cmax of VH4011499 when co-administered with Ritonavir

    Time frame: Day 26

  3. Cmax of VH4011499 when co-administered with Efavirenz

    Time frame: Day 37

  4. Cmax of VH4011499 when co-administered with Carbamazepine

    Time frame: Day 41

  5. Area under the concentration-time curve from 0 to tau [AUC(0-t)] of VH4011499 when administered alone

    Time frame: Day 1 for Cohorts 1, 2 and 3

  6. AUC(0-t) of VH4011499 when co-administered with Ritonavir

    Time frame: Day 26

  7. AUC(0-t) of VH4011499 when co-administered with Efavirenz

    Time frame: Day 37

  8. AUC(0-t) of VH4011499 when co-administered with Carbamazepine

    Time frame: Day 41

  9. Area under the concentration-time curve from 0 to infinity [AUC(0-inf)] of VH4011499 when administered alone

    Time frame: Day 1 for Cohorts 1, 2 and 3

  10. AUC(0-inf) of VH4011499 when co-administered with Ritonavir

    Time frame: Day 26

  11. AUC(0-inf) of VH4011499 when co-administered with Efavirenz

    Time frame: Day 37

  12. AUC(0-inf) of VH4011499 when co-administered with Carbamazepine

    Time frame: Day 41

  13. Cmax of Metformin when administered alone

    Time frame: Day 1

  14. Cmax of Metformin when co-administered with VH4011499

    Time frame: Day 16

  15. AUC(0-t) of Metformin when administered alone

    Time frame: Day 1

  16. AUC(0-t) of Metformin when co-administered with VH4011499

    Time frame: Day 16

  17. AUC(0-inf) of Metformin when administered alone

    Time frame: Day 1

  18. AUC(0-inf) of Metformin when co-administered with VH4011499

    Time frame: Day 16

  19. Cmax of Digoxin when administered alone

    Time frame: Day 1

  20. Cmax of Digoxin when co-administered with VH4011499

    Time frame: Day 16

  21. AUC(0-t) of Digoxin when administered alone

    Time frame: Day 1

  22. AUC(0-t) of Digoxin when co-administered with VH4011499

    Time frame: Day 16

  23. AUC(0-inf) of Digoxin when administered alone

    Time frame: Day 1

  24. AUC(0-inf) of Digoxin when co-administered with VH4011499

    Time frame: Day 16

  25. Cmax of Rosuvastatin when administered alone

    Time frame: Day 5

  26. Cmax of Rosuvastatin when co-administered with VH4011499

    Time frame: Day 22

  27. AUC(0-t) of Rosuvastatin when administered alone

    Time frame: Day 5

  28. AUC(0-t) of Rosuvastatin when co-administered with VH4011499

    Time frame: Day 22

  29. AUC(0-inf) of Rosuvastatin when administered alone

    Time frame: Day 5

  30. AUC(0-inf) of Rosuvastatin when co-administered with VH4011499

    Time frame: Day 22

  31. Cmax of Pitavastatin when administered alone

    Time frame: Day 1

  32. Cmax of Pitavastatin when co-administered with VH4011499

    Time frame: Day 17

  33. AUC(0-t) of Pitavastatin when administered alone

    Time frame: Day 1

  34. AUC(0-t) of Pitavastatin when co-administered with VH4011499

    Time frame: Day 17

  35. AUC(0-inf) of Pitavastatin when administered alone

    Time frame: Day 1

  36. AUC(0-inf) of Pitavastatin when co-administered with VH4011499

    Time frame: Day 17

Secondary outcomes

  1. Number of participants with adverse events (AEs), overall and by grade.

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. The intensity of AEs is reported based on the Division of acquired immunodeficiency syndrome (DAIDS) grading scale, where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=potentially life-threatening, Grade 5=death.

    Time frame: Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.

  2. Number of participants with AEs leading to study treatment discontinuation

    Time frame: Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.

  3. Number of participants with change from baseline in alanine transaminase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), direct bilirubin and total bilirubin

    Time frame: Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.

  4. Number of participants with maximum toxicity grade increase in alanine transaminase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), direct bilirubin and total bilirubin

    The toxicity is reported based on DAIDS grading scale, where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=potentially life-threatening, Grade 5=death.

    Time frame: Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.

  5. Time to maximum plasma concentration (Tmax) of VH4011499 when administered alone.

    Time frame: Day 1 for Cohorts 1, 2 and 3

  6. Tmax of VH4011499 when co-administered with Ritonavir

    Time frame: Day 26

  7. Tmax of VH4011499 when co-administered with Efavirenz

    Time frame: Day 37

  8. Tmax of VH4011499 when co-administered with Carbamazepine

    Time frame: Day 41

  9. Apparent oral clearance (CL/F) of VH4011499 when administered alone

    Time frame: Day 1 for Cohorts 1, 2 and 3

  10. CL/F of VH4011499 when co-administered with Ritonavir

    Time frame: Day 26

  11. CL/F of VH4011499 when co-administered with Efavirenz

    Time frame: Day 37

  12. CL/F of VH4011499 when co-administered with Carbamazepine

    Time frame: Day 41

  13. Apparent terminal half-life (t1/2) of VH4011499 when administered alone

    Time frame: Day 1 for Cohorts 1, 2 and 3

  14. t1/2 of VH4011499 when co-administered with Ritonavir

    Time frame: Day 26

  15. t1/2 of VH4011499 when co-administered with Efavirenz

    Time frame: Day 37

  16. t1/2 of VH4011499 when co-administered with Carbamazepine

    Time frame: Day 41

  17. Cmax of VH4011499 when co-administered with Metformin and Digoxin

    Time frame: Day 16

  18. AUC(0-t) of VH4011499 when co-administered with Metformin and Digoxin

    Time frame: Day 16

  19. AUC(0-inf) of VH4011499 when co-administered with Metformin and Digoxin

    Time frame: Day 16

  20. Cmax of Ritonavir when co-administered with VH4011499

    Time frame: Day 26

  21. AUC(0-t) of Ritonavir when co-administered with VH4011499

    Time frame: Day 26

  22. AUC(0-inf) of Ritonavir when co-administered with VH4011499

    Time frame: Day 26

  23. Cmax of Efavirenz when co-administered with VH4011499

    Time frame: Day 37

  24. AUC(0-t) of Efavirenz when co-administered with VH4011499

    Time frame: Day 37

  25. AUC(0-inf) of Efavirenz when co-administered with VH4011499

    Time frame: Day 37

  26. Cmax of Carbamazepine when co-administered with VH4011499

    Time frame: Day 41

  27. AUC(0-t) of Carbamazepine when co-administered with VH4011499

    Time frame: Day 41

  28. AUC(0-inf) of Carbamazepine when co-administered with VH4011499

    Time frame: Day 41

  29. Cmax of VH4011499 when co-administered with Rosuvastatin

    Time frame: Day 22

  30. AUC(0-t) of VH4011499 when co-administered with Rosuvastatin

    Time frame: Day 22

  31. AUC(0-inf) of VH4011499 when co-administered with Rosuvastatin

    Time frame: Day 22

  32. Cmax of VH4011499 when co-administered with Pitavastatin

    Time frame: Day 17

  33. AUC(0-t) of VH4011499 when co-administered with Pitavastatin

    Time frame: Day 17

  34. AUC(0-inf) of VH4011499 when co-administered with Pitavastatin

    Time frame: Day 17

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_28May2026.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.viiv-studyregister.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Mar 2027, 3 months later.

Of 74 industry-sponsored phase 1 interventional studies under HIV Infections, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's planned 3 months is below that.

Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartEst.
Nov 16, 2026
Primary completionEst.
Mar 12, 2027
CompletionEst.
Mar 12, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07939594
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Nov 16, 2026 (estimated)
Primary completion
Mar 12, 2027 (estimated)
Completion
Mar 12, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dezecapavir

Start the discussion